Göttingen Comprehensive Cancer Center

Applying tomorrow’s chances today

In order to research cancer, its causes, and - above all - new treatment ideas, clinical and biomedical researchers work hand in hand at the Göttingen Comprehensive Cancer Center. A special focus lies on translational research, where scientists use modern research methods to transfer results from fundamental biomedical research to clinical practice. 

We closely cooperate with many institutions, for example our biobank, the institute for pathology and the UMG Study Center. Additionally, the Göttingen Comprehensive Cancer Center is part of several (inter-)national cooperative projects, i.e. the International Cancer Genome Consortium [German]

Young researchers receive special support at the Göttingen Comprehensive Cancer Center. The Max-Eder-Young-Working-Groups-Programme of the German Cancer Aid [German] currently sponsors three working groups at the Cancer Center. 

These diverse research activities allow us to offer new and innovative therapy concepts to patients with different cancers as part of clinical trials. A list of all our publications is available in PubMed, the database of the National Library of Medicine (USA).  

You can find more information on research focus areas at the University Medical Center Göttingen here

Translational Research

Hände mit Pipette im Labor

Clinical Trials

Clinical trials facilitate development of innovative treatment methods or substances.

Mikroskop im Labor

UMG Biobank

Researchers can access high quality biomaterial for research purposes through the UMG biobank.

Pipette im Labor

Scientific Infrastructure

Core facilities that allow access to individual large-scale instruments as well as technology platforms are increasingly important to life science research.

Clinical Research Unit 5002

Characterization and targeting of the genome dynamics aiming for subtype-specific therapy of pancreatic ductal adenocarinoma

Pancreatic ductal adenocarcinoma (PDAC) remains a major challenge in cancer medicine. The aggressive tumor biology and remarkable resistance to conventional anti-tumor treatments are reflected in a 5-year PDAC survival rate of less than 8%. Despite significant scientific and clinical efforts the dismal prognosis of PDAC has remained unchanged for almost 30 years, and PDAC has been predicted to become the second leading cause of cancer related death within this decade.

Our Clinical Research Unit 5002 (CRU 5002) focuses on defined molecular subgroups of PDAC and explores subtype-specific genome dynamics and their implications on PDAC progression and therapy resistance. We believe that our findings can provide unique and novel avenues to refine PDAC treatment strategies towards stratification-based precision medicine, thus improving the outcome of PDAC patients.

Follow us